Cancer, Rectal cancer
ANLAdlai Nortye BiopharmaCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy in Cancer, Rectal cancer. The expected timing is based on the latest available company guidance and may change.
ARTEMIS. 5/22/24- Encouraging Phase Ib results. First Patient Dosed in Ph2 08/14/26:- ARTEMIS passed futility analysis in March 2026. Topline Phase 2 results are expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.